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Structure-activity relationship homology (SARAH): 
a conceptual framework for drug disclovery in the 
genomic era 
Stephen V Frye 
Extension of the traditional pharmacological approach of 
protein target dassification to whole target systems has 
the potential to relate elements of protein sequence to 
the structure-activity relationship (SAR) of small mol- 
ecules that can modulate protein action. Grouping 
potential drug discovery targets into families based on 
the relatedness of their SAR provides a means to trans- 
late the information from genome-sequencing efforts 
into knowledge that will aid in the discovery of drugs. 
Address: Division of Chemistry, Glaxo Wellcome Inc., 3.4134, 
5 Moore Drive, Research Triangle Park, NC 27709, USA. 
E-mail: svf351 1 @glaxowellcome.com 
Chemistry & Biology January 1999. 6:R3-R7 
http://biomednet.com/elecref/10745521006R0003 
0 Current Biology Ltd ISSN 1074-5521 
Structure-activity relationship homology (SARAH) 
Structure-activity relationships (SARs) emerge from an 
analysis of how changes in small-molecule structure 
effect activity versus a particular molecular target. SAR 
for a set of small molecules can he either srmilar between 
protein targets? or distinct. The idea of affinity finger- 
printing proteins with small molecules has been previ- 
ously discussed as a method to select small-molecule sets 
for subsequent screening that are enriched in high-affin- 
ity compounds. The notion that affinity fingerprinting 
could also provide a quantitative measure of similarity 
between disparate proteins was also suggested [l]. Build- 
ing upon this idea, targets that share SAR can he thought 
of as SAR homologous. SARAH is a convenient acronym 
for this relationship. This functional definition of relat- 
edness between proteins has a long history in pharmacol- 
ogy. For example, the receptors of the sympathetic and 
parasympathetic nervous system were largely described 
and characterized prior to knowledge of their amino-acid 
sequence, and small-molecule agonist and antagonist 
activity was used extensively to classify these proteins 
[Z]. With the advent of sequence information to group 
proteins into classes, this form of functional definition 
has become less widely used. The SARAH between pro- 
teins is uniquely valuable for assessing potential selectiv- 
ity issues, however, when searching for potent and 
selective small molecules versus protein targets. Indeed, 
combinatorial chemistry and high-throughput screening 
provide the means to establish extensive empirically 
derived SARAH protein families. The resurrection of 
this classification technique is likely to he a very power- 
ful tool in hioorganic chemistry and drug discovery. 
Systems-based research 
The discovery of drugs was initially driven by a focus on 
physiology and empirical observations of the effect of 
small rrlolecules in animal models of disease. Biochem- 
istry and pharmacology then drove a phase of drug discov- 
ery based on understanding the molecular foundation for 
physiological processes. Medicinal chemistry programs 
could then focus around the knowledge of endogenous 
small-mnlecule mediators 01 enzymatic mechanism 
instead of in -~lie~o empiricism. The last decade has seen an 
emergence of more systematic approaches to drug discov- 
ery through a focus on particular protein families that 
have pmven amenable to intervention by small mole- 
cules: 7-transmemhrane (71‘1\/1) reCeptcJrS, nuclear 
hormone receptors, ion channels, proteases and protein 
kinases. The ability to systematically develop the molec- 
ular biology (cloning, expression and purification), bio- 
chemistry (screening) and medicinal chemistry within a 
protein target system allows for great efficiencies in all 
stages of preclinical drug discovery. This approach also 
allows scientific expertise to grow and flourish in an age 
where irdividual projects may only last for 2-3 years. 
Systems-based drug discovery starts with a target class of 
proven value in drug discovery and then seeks t(J use 
small molecules to make the connection to disease. I will 
refer to this form of research as ‘systems-based research’ 
[3]. The protein kinase family is such an emerging system 
for drug discovery. 
The information challenge 
Biomedical science is experiencing a flood of new infor- 
mation due to the ability of the technological advances in 
DNA manipulation and sequencing to rapidly provide the 
sequence:; of all expressed genes and entire genomes [4]. 
Within the context of drug discovery in the protein kinase 
arena, thir; information holds promise and challenges for 
the future. The primary sequence of all protein kinases in 
human and many pathogen genomes will soon he a\,ail- 
able, as well as some genetic disease association for many 
kinases or. more likely, the pathways in which they func- 
tion. The existence of this information raises a number of 
questions: how will potential targets he prioritized for drug 
discovery efforts in a knowledge-based manner from 
among the estimated 3000 protein kinases? How can 
selectivity he assessed in a genomic context? (Currently 
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Figure 1 
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Sorting different kinases into SARAH families 
using small-molecule inhibitors. From an initial 
single family defined by ATP binding, the 
number of SARAH families increases as the 
chemical diversity of small-molecule kinase 
inhibitors increases. 
many companies screen against 10-20 kinases for selectiv- 
ity determinations; surely this is meaningless in such a 
large protein family.) Is there a conceptual framework that 
will allow us to rise to these challenges? 
SARAH applied to protein kinases 
Most protein kinases bind ATl? Ignoring differences in 
Knl and taking ATP binding as the sole discriminator, 
most kinases can be assigned to the same SARAH 
‘family’. The small-molecule structure (ATP) binding to 
their active site defines this family. (And indeed, many 
other proteins belong to this family based solely on ATP 
binding.) This is the minimal SARAH family for protein 
kinases, and certain conserved residues contribute to the 
binding of ATP and the catalytic mechanism of phos- 
phate transfer. New family members can be picked out of 
the expressed sequence tag (EST) databases due to the 
sequence conserv-ation that preserves this function. When 
we enter the world of small-molecule inhibitors, however, 
all protein kinases are no longer equivalent in terms of 
SARAH. With increasing diversity of inhibitors the previ- 
ously irreducible SARAH family is split into subfamilies. 
This sorting of kinases into families by small molecules is 
entirely analogous to the traditional assignment of 7TM 
receptor families by their small-molecule agonists and 
antagonists and is similarly independent of any assump- 
tions about the binding site of the small molecule. This 
concept is represented in Figure 1. 
As it turns out, the vast majority of potent protein kinase 
inhibitors are, in fact, competitive with ATP and selectivity 
arises from differences in pockets adjacent to the ATP- 
binding region that ATP itself does not occupy ([5] and ref- 
erences therein). Given that the sequence determinants of 
ATP binding are distinct from substrate- and protein- 
recognition determinants, we can anticipate that SARAH 
families based on ATP-competitive small molecules will 
not necessarily be coincident with biochemical families or 
overall sequence homology families (serine/threonine 
versus tyrosine, or receptor versus nonreceptor versus 
nuclear). In fact, these SARAH families will share binding 
function or ‘shape’ and perhaps sequence conservation 
around the ATP-binding site. 
Potential applications of SARAH 
By screening a common and diverse set of small molecule 
inhibitors against a set of protein kinases a SARAH assign- 
ment will be derived for each kinase [l]. Branch points in 
the family tree could be defined by overall correlation of 
pICs,, values between kinases. If a sufficient number of 
kinases is screened (undefined at this point), SARAH fami- 
lies will probably be populated by enough members to cor- 
relate amino-acid changes in the ATP-binding region (or 
ATP active-site shape based on X-ray crystallography and 
modeling) with the overall family assignments. Establish- 
ment of this correlation between sequence and small-mole- 
cule SAR becomes a ‘Rosetta Stone’ for translating 
protein-kinase sequence into the domain of drug discovery. 
Another important result of the SARAH family assign- 
ments is the fact that it provides a knowledge-based way to 
choose selectivity assays. Intelligent screening for potential 
cross-reactive kinases would examine members of the 
same SARAH family where, given the current state of 
chemical diversity, selectivity is anticipated to be a 
problem. In addition, representative kinases, especially 
ones implicated as important in physiology/toxicology, 
would be chosen for screening from other SARAH families 
in order to ensure that selectivity is maintained. Prioritiza- 
tion of kinase drug discovery targets could be based par- 
tially on selectivity/toxicity Issues within this protein class 
as evidenced by the SARAH family to which any new 
target may belong. Potential targets that lie close in 
SARAH homology to known kinases whose inhibition is 
deleterious would be of lower priority than kinases whose 
SARAH assignment is less related to kinases to be avoided. 
Although the SARAH family structure arises from small 
molecules sorting proteins into classes, the reciprocal 
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Figure 2 
The drug discovery process flow using 
SARAH families. Once an initial core 
compound set has been created, it may be 
used to empirically classify any new kinase 
screened into a SARAH fami!y. The SARAH 
assignment then provides the basis for 
establishing appropriate selectivity assays and 
active compounds from the core set may be 
useful for target validation work (assessment 
of connection of the target to disease of 
interest). The possibility of rapidly progressing 
many ktnases to this level of understanding 
can aid in prioritization. When a correlation 
between sequence and SARAH can be made 
with confidence (curved arrow on far left of 
figure), sequence alone could provide the 
knowledge necessary for target prioritization. 
V 1 klnasr targets ] 
Rapid lead optimvation, 
ability to rapIdly address 
genetic disease association 
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relationship is also worth examining: kinases sort small 
molecules into clusters in pIC,, space that is dimension- 
ally as large as the number of kinases screened ([l]: L.I’ 
Kuyper, personal communication). Compounds are clus- 
tered due to their profile (correlated affinity) across the 
kinases screened. Within a cluster, compounds presum- 
ably share a similar shape/charge interaction across the 
current set of kinases screened. These compound clusters 
could fragment as biological diversity increases (i.e., more 
are kinases screened), in the same manner as previously 
irreducible SARAH families when chemical diversity 
increases. In analogy to the SARAH families’ ability to 
correlate sequence with SAR, because of a shared active- 
site shape, molecules within a cluster share a shape that 
defines their activity across the set of kinases. At any point 
in the development of the biological and chemical diver- 
sity of this system it will be possible to select the com- 
pounds and the kinases that maximally differentiate each 
other. This core set (training set in [l]) then becomes the 
basis for reducing the number of compounds and kinases 
necessary for systematic exploration of new kinases and 
compounds. A representation of the idealized process flow 
within this conceptual framelvork appears in Figure 2. 
What is chemical diversity anyway? 
The interplay between chemical and biological diversity 
in this system is apparent in the previous discussion and 
it is of interest to ask how the number of SARAH fami- 
lies might relate to chemical diversity. Figure 3 depicts a 
purely speculative hypothesis of this relationship for 
protein kinases. 
The hypothesis implied in Figure 3 is that as chemical 
diversity increases the number of SARAH families 
approaches a limit defined as nmcd (number of families at 
maximutn chemical diversity) and that this number will be 
less thar N, the total number of protein kinases in the 
genome (or genomes). This seems likely in the kinase 
system E’ecause of the large number of members in this 
class ant! the fact that potent small-molecule inhibitors 
generally interact in the somewhat conserved ,4TP- 
binding site. If nmcd/N is equal to 0.1 then a SARAH 
family would, on average, have ten members. Chemical 
diversity that explores other regions of the kinase could 
obviously change the assumptions behind this proposition. 
‘I’he model does, however, provide an operational defini- 
tion of chemical diversity that is dependent upon the 
extrinsic properties of small molecules and the protein 
class targeted. In the realm of drug discovery, it seems that 
the most useful definition of ‘chemical diversity’ is that it 
is the property of a set of compounds which increases as 
the number of SARAH families increases. A correlation 
analysis between this empirical and extrinsic definition 
with the intrinsic properties of small molecules would 
seem to provide an appropriate basis for progress in the 
area of defining how chemical diversity varies with the 
intrinsic properties of molecules. (See [I] for an example 
using principle component analysis.) In the broader 
context of systems-based research, the ratio of nmcd/N may 
be a fundamental characteristic of the protein family (or 
the particular site targeted), and methods to predict this 
characteristic would have great value for sorting the 
human gelome into tractable classes of proteins for dis- 
covery of potent and selective drugs. 
Initial results 
Accumulation of a sufficient sized data set to begin to test 
the hypotl-eses resident in this conceptual framework is 
difficult el,len within a large pharmaceutical company. 
The concepts presented in this discussion are therefore 
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Figure 3 
N = number of targets in this class in the human (or other) genome(s) 
n mrd = number of families at maximal chemical diversity 
n = current number of 
SARAH fx-- 
f 
- = a function of protein family 
n 
- = a function of current chemical 
bed diversity 
The interplay between chemical and biological 
diversity in the SARAH families. The number 
of SARAH families (n) increases as the 
diversity of small molecules screened 
increases. At some point kinases may be 
indistinguishable from each other with small 
molecule inhibitors. The number of SARAH 
families at the limit of maximum chemical 
diversity (mcd), nmod 1 compared to the total 
number of kinases in the genome (N) is 
expressed as the ratio n,,,JN. This ratio is a 
fundamental property of a target class (or 
particular active-site targeted). 
Chemical diversity 
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still mostly speculative at this stage. Some early results 
support the value of the general ideas, however. Figure 4 
is a plot of compound selectivity index (defined as the 
highest pIC,, minus the average of all other pIC,, values) 
versus the highest pIC,, determined for that compound. 
The general correlation of potency and selectivity is con- 
sistent with the notion that more potent compounds are 
more finely tuned for the active site where they have a 
high affinity. This also means that the > 10 kinases 
against which this data was accumulated are somewhat 
distinct in their active-site shape. As the number of 
kinases screened versus this same set of compounds 
increases, the average selectivity of the compounds could 
increase, decrease or remain unchanged. Increasing selec- 
tivity at constant chemical diversity (i.e. the same com- 
pound set) is consistent with adding kinases of low 
SARAH to the current set of kinases. Decreasing selectiv- 
ity indicates that the kinases added are of higher SARAH 
than the current set of kinases. There will be an analo- 
gous relationshxp as new compounds are added. More 
diverse compounds will increase the average selectivity, 
whereas less diverse will decrease it. 
Translating information to knowledge 
The general SARAH approach and related concepts dis- 
cussed above are an attempt to build a framework in 
which chemistry and biology can most productively inter- 
face with the newer science of genomics [6]. The tech- 
niques of the yeast two-hybrid assay and differential gene 
expression can add significantly to this effort by bringing 
disease association and target validation information into 
this systems-based approach to protein kinases. The inter- 
relationship of kinases based on protein partners and 
downstream genetic regulation is an important component 
of the ‘Rosetta Stone’ that can translate information into 
useful knowledge for the discovery of drugs. The combi- 
nation of this systematic approach to SAR information 
with the power of X-ray crystallography and structure- 
based drug design also holds great promise for compound 
library design in the future. 
Figure 4 
b------y 
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Highest plC,, across all kinases 
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The relationship between potency and selectivity for a set of small- 
molecule kinase inhibitors screened against > 10 protein kinases. 
Compound selectivity index is defined as the highest PIG,, minus the 
average of all other plC,,s. 
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The questions posed at the beginning of this paper cut 
across many areas of biomedical research, especially in the 
pharmaceutical industry. The ability to create a meaning- 
ful interface between biology, chemistry and genomics, as 
presented here, could provide an entry into knowledge- 
based drug discovery in the context of the complete 
human genome. 
Acknowledgements 
The author recognizes Lee Kuyper, Mike Cory and Kevan Shokat for insight- 
ful discussions of the SARAH approach and the work of Kauvar ef al. [II as 
the foundation upon which SARAH rests. 
References 
1. Kauvar, L.M., ef al., & Rocke, D.M. (1995). Predictrng ligand binding to 
proteins by affinity fingerprinting. Chem. Biol. 2, 107-l 18. 
2. Lefkowitz,-R.J., Hoffman; B.B. &Taylor, P. (1990). Neurohumoral 
Transmission: the autonomic and somatic motor nervous systems. In 
Goodman and Gilman’s The Pharmacological Basis of 
Therapeutics. (Gilman, A.G., Rail, T.W., Nies, A.S., Taylor, P., eds), 
Pergamon Press, New York. 
3. Lehman, J., et a/., & Williamson, R. (1996). Systematization of 
research. Nature Supp. 384, 5. 
4. Jasny, B.R. & Hines, P.J. (1998). A genome sampler. Science 282, 651. 
5. Toledo, L.M. & Lydon, N.B. (1997). Structures of staurosporine bound 
to CDKP and cAPK - new tools for structure-based design of protein 
kinase inhibitors. Structure 5, 1551-l 556. 
6. Schreiber, S.L. (1998). Chemical genetics resuhng from a passion for 
synthetic organic chemistry. Bioorg. Med. Chem. 6, 1 127-l 152. 
